There have been reports of noninfectious pneumonitis (including some with pulmonary hypertension as a secondary event), infections, and renal failure (including acute renal failure) in patients...
Advanced HR+, HER2-Negative Breast Cancer
Welcome to the AFINITOR Nurse Center
An online collection of educational tools and treatment resources to help the nursing community care for their patients with advanced breast cancer.
Dr O’Shaughnessy discusses stomatitis patient education and management strategies
Joyce O’Shaughnessy, MD (with Josie Divers, RN)
Helpful tips for the patient in managing the treatment journey with AFINITOR® (everolimus) Tablets.
Patient Counseling Kit
Educate your patients about AFINITOR. The kit includes a patient education brochure, products, and resources patients can use while on therapy. To obtain kits, click the Request a Sales Rep Visit button below.
Clinical Educators (CEs) support oncology nurses and other office staff in their role of assessing, educating, and managing patients at every step of their treatment journey. CEs can provide office staff with patient education materials, side effect assessment tools, and strategies to help patients cope with some of the side effects from advanced breast cancer treatments.
Contact your local Clinical Educator (CE) for more information about advanced breast cancer and treatment options
Upcoming Nursing Conferences
Check out these upcoming conventions and discover the latest in clinical care:
Oncology Nursing Society (ONS) Conference
Association for Value-Based Cancer Care (AVBCC) Conference
Academy of Oncology Nurse and Patient Navigators (AONN)
American Society of Clinical Oncology (ASCO)
Breast Cancer Symposium
San Antonio Breast Cancer Symposium (SABCS)
AFINITOR is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole.
Important Safety Information
AFINITOR is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients.
Angioedema With Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors
Impaired Wound Healing
Laboratory Tests and Monitoring
Please see full Prescribing Information.